From microarray to bedside: targeting NF-kappaB for therapy of lymphomas.
Cancer Institute of New Jersey, University of Medicine and Dentistry of New Jersey-Robert Wood Johnson Medical School, New Brunswick, New Jersey, New Brunswick, NJ, USA.Clinical Cancer Research (impact factor: 7.74). 02/2005; 11(1):2-6. pp.2-6
Data provided are for informational purposes only. Although carefully collected, accuracy cannot be guaranteed. The impact factor represents a rough estimation of the journal's impact factor and does not reflect the actual current impact factor. Publisher conditions are provided by RoMEO. Differing provisions from the publisher's actual policy or licence agreement may be applicable.